Medicare to Pay for Image Guidance in Biopsy of Palpable Breast Lesions

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

WASHINGTON-Medicare will soon cover image guidance techniques, such as stereotactic systems and ultrasound, used to biopsy palpable breast lesions that are difficult to biopsy with palpitation alone. However, contractors who administer Medicare benefits "have the discretion to decide what types of palpable lesions are difficult to biopsy using palpitation," the Centers for Medicare and Medicaid Services said. The new coverage will begin later this year and will not be retroactive. Medicare has covered image guidance to assist the biopsy of nonpalpable lesions since 1999.

WASHINGTON—Medicare will soon cover image guidance techniques, such as stereotactic systems and ultrasound, used to biopsy palpable breast lesions that are difficult to biopsy with palpitation alone. However, contractors who administer Medicare benefits "have the discretion to decide what types of palpable lesions are difficult to biopsy using palpitation," the Centers for Medicare and Medicaid Services said. The new coverage will begin later this year and will not be retroactive. Medicare has covered image guidance to assist the biopsy of nonpalpable lesions since 1999.

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content